NLRP3 and COVID-19: Our data indicate that inhibition of NLRP3 inflammasome can reduce “cytokine storm” and lung injury caused by SARS-CoV-2 infection, suggesting that NLRP3 inflammasome is a potential target for COVID-19 therapy.